Home Your basket
• Mucosal melanomas of the ...
   Price 8.50 €
• Persistent stapedial arte...
   Price 5.50 €
• Treatment and rehabilitat...
   Price 10.50 €
• Adenocarcinoma of the end...
   Price 8.50 €
• Exploration of the otolit...
   Price 10.50 €
• The effects of treatments...
   Price 14.00 €
• Papillary carcinoma arisi...
   Price 5.50 €
• Enlarged marginal incisio...
   Price 10.50 €
• Type 1 tympanoplasties in...
   Price 12.00 €
• Thyroid tuberculosis asso...
   Price 5.50 €
• Reliability of CT-Scan in...
   Price 8.50 €
• Comparative study of anal...
   Price 14.00 €
• The pedicle superficial t...
   Price 10.50 €
• Hearing aid : practical a...
   Price 8.50 €
• Forcing the voice : the c...
   Price 5.50 €
• Rhinoplasty: Morphodynami...
   Price 10.50 €
• Results of alginate and h...
   Price 10.50 €
• Migrant foreign body of t...
   Price 10.50 €
• Otomycosis...
   Price 10.50 €
• International Conference ...
   Price 5.50 €
• Voice related quality of ...
   Price 10.50 €
• Unsteadiness and drunkenn...
   Price 10.50 €
• A report of two cases of ...
   Price 5.50 €
• Aberrant internal carotid...
   Price 5.50 €
• Interest of the cervical ...
   Price 10.50 €
• Treatment of acute mastoi...
   Price 8.50 €
• Laryngeal paraganglioma m...
   Price 8.50 €
• Termino-terminal hypoglos...
   Price 10.50 €
• Nasosinusal tumours: Anat...
   Price 14.00 €
• Utility of positron emiss...
   Price 8.50 €
• Surgical management of ma...
   Price 10.50 €
• Partial hearing recovery ...
   Price 5.50 €
• Mucus physiopathology, up...
   Price 12.50 €
• A protocol for post-opera...
   Price 5.50 €
• Unusual location of pleom...
   Price 12.50 €
• Induction chemotherapy an...
   Price 10.50 €
• Surgery for hyperthyroidi...
   Price 5.50 €
• Frontal sinus osteoma com...
   Price 5.50 €
• New technique of myringop...
   Price 5.50 €
• A comparative study of br...
   Price 10.50 €
• Usher type I syndrome in ...
   Price 10.50 €
• Kikuchi's disease as the ...
   Price 10.50 €
• Treatment by enlargement ...
   Price 10.50 €
• Middle ear tuberculosis e...
   Price 5.50 €
• Early PTH assay after tot...
   Price 10.50 €
• A new tongue plate for us...
   Price 5.50 €
• Evaluation of the use of ...
   Price 8.50 €
• New trends in rhinoplasty...
   Price 10.50 €
• Benign paroxysmal positio...
   Price 10.50 €
• Prospective study on 43 s...
   Price 10.50 €
• Tuberculosis of the laryn...
   Price 5.50 €
• A rare case of sarcoidosi...
   Price 5.50 €
• The input of autogenous g...
   Price 10.50 €
• A rare tumor of the parap...
   Price 5.50 €
• Dysphonia in children: Re...
   Price 12.50 €
• A specific plain X-ray in...
   Price 8.50 €
• Treatment of children wit...
   Price 8.50 €
• Lingual granuloma of preg...
   Price 5.50 €
• Pathophysiology of choles...
   Price 10.50 €
• The role of larynx kinest...
   Price 10.50 €
• Audit of headache followi...
   Price 5.50 €
• Sinonasal malignant schwa...
   Price 5.50 €
• Sphenochoanal polyp: Repo...
   Price 5.50 €
• Atelectasis of the maxill...
   Price 8.50 €
• The clinical significance...
   Price 5.50 €
• Facial nerve monitoring i...
   Price 10.50 €
• Granular cell tumours (Ab...
   Price 8.50 €
• Autologous cartilaginous ...
   Price 10.50 €
• Clinical signs and correl...
   Price 10.50 €
• Nasopharyngeal tuberculos...
   Price 5.50 €
• Adenoid cystic carcinoma ...
   Price 10.50 €
• The pedicled musculo-cuta...
   Price 8.50 €
• Tuberculous acute mastoid...
   Price 5.50 €
• A giant lipoma of parapha...
   Price 8.50 €
• The effects of passive sm...
   Price 10.50 €
• Temporomandibular dysfunc...
   Price 10.50 €
• Vocal effectiveness in sp...
   Price 10.50 €
• Cosmetic radiofrequency...
   Price 10.50 €
• Laryngeal pemphigus...
   Price 5.50 €
• Comparative results of ty...
   Price 10.50 €

Total Order 705.00 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 4 - 2008 o

OTONEUROLOGY

Disability in patients with Menière’s disease following the use of two different treatment modalities: Betahistine and intratympanic gentamicin


Authors : Enrique-Gonzalez A, Sánchez-Ferrándiz N, Pérez-Fernández N. (Pamplona)

Ref. : Rev Laryngol Otol Rhinol. 2008;129,4:249-254.

Article published in english
Downloadable PDF document english



Summary : Objective: The objective of this study was to assess the level of residual disability and handicap in patients with Menière’s disease (MD) that were free of new vertigo spells 2 years after having been administered treatment with either oral medication or with intratympanic gentamcin. Setting: University hospital. Tertiary medical center. Material and method: 40 patients with MD were included in this study, of which 20 were treated with oral medication (betahistine) and 20 with intratympanic gentamicin; intratympanic gentamicin was for patients considered failures for the oral medication treatment. All of them are free of new vertigo in the 16-24 month period after beginning the treatment. They were matched by age and disease duration. Disability and handicap were assessed with conventional questionnaires at the time of inclusion and 2 years after beginning oral medication or ended the intratympanic gentamicin treatment. According to the treatment two groups were created: oral medication treatment and intratympanic gentamicin treatment. Results: The amount of disability before treatment was higher in patients treated with intratympanic gentamicin than in those under oral medication; However, after treatment when no more vertigo spells takes place, this disability is significantly reduced and becomes similar for both groups of patients. In patients treated with oral medication the items reflecting the intensity of vertigo spell, the impact of vertigo in daily activities, the perception of quality of life and level of somatization do not show a significant reduction. Conclusion: The number or frequency of vertigo spells are very relevant for the process of disability and handicap of patients with MD when that is low or when oral medication is sufficient to eliminate vertigo spells. However when that number is high and the only possibility to arrest those vertigo spells is the use of intratympanic gentamicin, fear of vertigo must be considered as an associated problem for the patient.

Price : 10.50 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE